SCHEMBL2773397

SCHEMBL2773397

Cc1ccccc1C(=O)CO

nearest known ligand 0.60

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ERCC5 P28715 1/20 0.60
FEN1 P39748 1/20 0.60
CTNNB1 P35222 6/20 0.51
WNT3A P56704 6/20 0.51
HPGD P15428 2/20 0.47
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
HTT P42858 1/20 0.44
TSHR P16473 2/20 0.43
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29639746 1.00 ERCC5 (0.60) ERCC5FEN1CTNNB1WNT3AHPGD
SCHEMBL30089517 0.84 CTNNB1 (0.68) ERCC5FEN1CTNNB1WNT3AHPGD
SCHEMBL8735550 0.84 ERCC5 (0.74) ERCC5FEN1CTNNB1WNT3AHPGD
SCHEMBL15979740 0.84 CTNNB1 (0.68) ERCC5FEN1CTNNB1WNT3AHPGD
SCHEMBL10770139 0.83 ESR1 (0.46) ERCC5FEN1CTNNB1WNT3AHPGD
SCHEMBL3704844 0.82 ERCC5 (0.60) ERCC5FEN1CTNNB1WNT3AHPGD
SCHEMBL364889 0.82 ERCC5 (0.60) ERCC5FEN1CTNNB1WNT3AHPGD
SCHEMBL31901342 0.82 ERCC5 (0.60) ERCC5FEN1CTNNB1WNT3AHPGD
SCHEMBL8053673 0.80 ERCC5 (0.58) ERCC5FEN1CTNNB1WNT3AHPGD
SCHEMBL168885 0.80 ERCC5 (0.58) ERCC5FEN1CTNNB1WNT3AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116715671-A Application of alpha-chromene spiropiperidine compound in preparation of 5-hydroxytryptamine 2C receptor agonist 苏州大学 2023-09-08 CN disclosed
US-11649218-B2 C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2023-05-16 US disclosed
CN-115068475-A Application of alpha-chromene spiropiperidine compounds in preparation of 5-hydroxytryptamine 2C receptor agonists 苏州大学 2022-09-20 CN disclosed
US-9950999-B2 Non-ionic low diffusing photo-acid generators INTERNATIONAL BUSINESS MACHINES CORPORATION (US) 2018-04-24 US disclosed
US-9950999-B2 Non-ionic low diffusing photo-acid generators INTERNATIONAL BUSINESS MACHINES CORPORATION (US) 2018-04-24 US disclosed
US-9950999-B2 Non-ionic low diffusing photo-acid generators INTERNATIONAL BUSINESS MACHINES CORPORATION (US) 2018-04-24 US disclosed
US-20180044284-A1 NON-IONIC LOW DIFFUSING PHOTO-ACID GENERATORS INTERNATIONAL BUSINESS MACHINES CORPORATION 2018-02-15 US disclosed
US-20180044284-A1 NON-IONIC LOW DIFFUSING PHOTO-ACID GENERATORS INTERNATIONAL BUSINESS MACHINES CORPORATION 2018-02-15 US disclosed
US-20180044284-A1 NON-IONIC LOW DIFFUSING PHOTO-ACID GENERATORS INTERNATIONAL BUSINESS MACHINES CORPORATION 2018-02-15 US disclosed
US-20160166526-A1 COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-16 US disclosed
EP-1875926-A1 STABLE EMULSION COMPOSITION Takeda Pharmaceutical Company Limited (JP) 2008-01-09 EP disclosed
WO-2007140183-A1 FXR AGONISTS ELI LILLY AND COMPANY (US) 2007-12-06 WO disclosed
US-7247653-B2 Pharmaceutical composition TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-07-24 US disclosed
WO-2007016525-A2 PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF COMPLEX DISEASES AND THEIR DELIVERY BY INSERTABLE MEDICAL DEVICES RESVERLOGIX CORP. (CA) 2007-02-08 WO disclosed
WO-2006095885-A1 ANTIREFLECTIVE FILM, METHOD OF MANUFUCTURING ANTIREFLECTIVE FILM, POLARIZING PLATE AND IMAGE DISPLAY DEVICE USING THE SAME FUJIFILM CORPORATION (JP) 2006-09-14 WO disclosed
CN-1768050-A Benzopyran compounds for the treatment of inflammation PHARMACIA CORP (US) 2006-05-03 CN disclosed
EP-0686636-B1 TRICYCLIC BENZAZEPINE AND BENZOTHIAZEPINE DERIVATIVES MEIJI SEIKA CO (JP) 2001-04-04 EP disclosed
US-5840895-A INTERMEDIATES FOR ANTIALLERGENS MEIJI SEIKA KABUSHIKI KAISHA (JP) 1998-11-24 US disclosed
US-5686442-A ANTIALLERGENS MEIJI SEIKA KABUSHIKI KAISHA (JP) 1997-11-11 US disclosed
EP-0686636-A1 TRICYCLIC BENZAZEPINE AND BENZOTHIAZEPINE DERIVATIVES MEIJI SEIKA KABUSHIKI KAISHA (JP) 1995-12-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11649218-B2 C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same ABL1, ABL2, MUSK ERCC5 4649/4885FEN1 4077/4885CTNNB1 1943/4885
US-20160166526-A1 COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT PMP22, GAP43, NGF ERCC5 1582/4885FEN1 1824/4885CTNNB1 3967/4885
US-20180044284-A1 NON-IONIC LOW DIFFUSING PHOTO-ACID GENERATORS PLG, PPARG, PKLR ERCC5 983/4885FEN1 4572/4885CTNNB1 3143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.